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COST-EFFECTIVENESS OF CETUXIMAB COMBINED WITH 
RADIOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED HEAD 
AND NECK CANCER IN TAIWAN
Chan AL1, Leung HW2, Lin SJ3
1Chi Mei Medical Center, Tainan, Taiwan, 2Taipei Medical University-Shuang Ho Hospital,, 
Jhonghe City, Taiwan, 3Kaohsiung Medical University, Kaohsiung , Taiwan
OBJECTIVES: The aim of this study was conducted to estimate the cost-effectiveness 
of cetuximab combined with radiotherapy compared to radiotherapy alone in patients 
with locally advanced squamous cell carcinoma of head and neck. METHODS: A 
decision-tree analysis was used to compare cetuximab combined with radiotherapy 
and radiotherapy alone in the treatment of patients with locally advanced squamous 
cell carcinoma of head and neck from the perspective of the Bureau of National Health 
Insurance(BNHI) in Taiwan. The model was based on individual patient data 
extracted from an international phase III trial. The direct medical costs of care were 
based on the reimbursement of Bureau of National Health Insurance in Taiwan. 
One-way sensitivity analyses were performed with varying the costs and clinical 
parameters. RESULTS: The incremental cost per quality-adjusted life-year for patients 
receiving radiotherapy in combination with cetuximab compared to radiotherapy 
alone was in the range of $70,469/yr to $542,334/yr in the base-case analysis. Sensitiv-
ity analysis showed the robust results. CONCLUSIONS: This study demonstrated the 
addition of cetuximab to high-dose radiotherapy regimen is likely to be cost-effective 
in consideration of higher locoregional control rate to be achieved compared to 
radiotherapy alone for locally advanced head and neck cancer in Taiwan.
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LEVELS TO INITIATE THERAPY CHANGE IN HER2+ METASTATIC 
BREAST CANCER
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OBJECTIVES: The goal of personalized medicine is to identify the right treatment for 
the right patient at the right time. Prior to treating metastatic breast cancer (MBC) 
patients with Herceptin, tumors are tested for overexpression of HER2. Still for many 
HER2 + patients (treated with herceptin), disease progression continues. It has previ-
ously been shown that for MBC changes in patients’ serum HER-2 levels during 
treatment is predictive of their eventual response to therapy. Through modeling and 
simulation we examine the potential impact of ceasing Herceptin therapy prior to the 
end of the planned treatment cycle for patients whose serum HER-2 levels predict an 
eventual lack of therapeutic response. METHODS: Markov Cycle Tree models were 
constructed to simulate disease progression and therapy for MBC patients using our 
custom simulation software, ProFound. The progression of disease was dependent on 
the patient’s current therapy: Herceptin, Tykerb, or Paclitaxel, and model parameters 
were based on meta-analysis of clinical trials. Patients are stratiﬁed into three sets: 
Serum HER-2 Increasing (>20%), Not Changing, and Decreasing (>20%). We com-
pared the following alternative treatment strategies: Paclitaxel, Herceptin, and initial 
Herceptin with change in therapy after 1 month based on changes in serum HER2. 
Patients removed from Herceptin either simply discontinued therapy or were switched 
to Tykerb. RESULTS: Compared with continued treatment with Herceptin, moving 
patients with >20% increase in Serum HER-2 to Tykerb resulted in an additional one 
life-month gained. All other strategies performed worse than continued Herceptin 
therapy, including moving patients whose Serum HER2 levels are not decreasing to 
Tykerb. This highlights the importance of identifying the right subset of patients who 
will beneﬁt from a change in therapy. CONCLUSIONS: A biomarker that can predict 
therapy failure prior to the end of treatment as part of the treatment decision-making 
process may extend the lives of patients.
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COST-EFFECTIVENESS OF LENOGRASTIM NEUTROPENIA DURATION 
IN ADULTS RECEIVING CHEMOTHERAPY FOR LEUKEMIA
Rutkowski J1, Derylo L1, Fedyna M1, Plisko R1, Lis J2, Wladysiuk M1
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OBJECTIVES: The aim of present analysis was to assess cost-effectiveness of leno-
grastim in comparison with other G-CSFs—ﬁlgrastim and pegﬁlgrastim in Polish 
settings (threshold is about 100,095 PLN). METHODS: Analysis covered time horizon 
of one chemotherapy cycle. A public payer perspective was adopted for cost analysis. 
The costs included were based on Polish NHF reference costs list. Data on time to 
ANC recovery, number of days with fever, length of hospital stay and antibiotics use 
were obtained from randomized controlled trials (RCTs) identiﬁed in the conducted 
systematic review. These included trials on prophylactic G-CSF use as well as trials in 
which only patients with neutropenia were included. Equations describing costs and 
QALY according to neutropenia and fever length, hospital stay and antibiotic use were 
established. RESULTS: Estimated QALY difference between lenograstim and ﬁlgras-
tim is 0.0041 (CI95%[0.0007; 0.0079]), compared to pegﬁlgrastim is 0.0039 
(CI95%[0.0004; 0.0077]). Total costs difference between lenograstim and ﬁlgrastim is 
−2,069 PLN (CI95%[−5,385; −1,039]) and compared to pegﬁlgrastim is 266 PLN 
(CI95%[−3,233; 3,633]). The ICER in comparison with pegﬁlgrastim is 68,424 PLN. 
Probability of lenograstim being cost-effective over ﬁlgrastim is 91.54% and over 
pegﬁlgrastim is 51.41%. Taking into account only trials where G-CSFs were used in 
neutropenia prophylaxis estimated QALY difference between lenograstim and ﬁlgras-
tim is 0.0049 (CI95%[0.0013; 0.0088]), compared to pegﬁlgrastim is 0.0047 
(CI95%[0.0011; 0.0086]). Total costs difference between lenograstim and ﬁlgrastim is 
−2,724 PLN (CI95%[−6,139; −475]) and compared to pegﬁlgrastim is −434 PLN 
(CI95%[−4,025; 2,996]). Probability of lenograstim being cost-effective over ﬁlgrastim 
is 96.12% and over pegﬁlgrastim is 66.82%. CONCLUSIONS: Lenograstim is domi-
nant over ﬁlgrastim and cost-effective in comparison with pegﬁlgrastim. Acknowledge-
ments: This analysis was supported by Sanoﬁ-Aventis.
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SURVEILLANCE OF HEPATOCARCINOMA IN COLOMBIA
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OBJECTIVES: The objetive of this paper is an analysis of cost effectiveness of a 
proposed clinical pathway for the surveillance of hepatocellular carcinoma in Colom-
bia compared to conventional management METHODS: Economic evaluation is 
performed by designing a Markov model to simulate two cohorts, one under a surveil-
lance program through the combined use of alpha-fetoprotein and ultrasound every 
6 months and another with the current monitoring scheme with a time horizon of 30 
years and age of onset of 30 years, a rate adjustment of 3% the initial cohort of 100 
patients RESULTS: The cost in the surveillance group is US $ 1,495.548 and 
unguarded arm is U.S. $ 798,714. With the surveillance program presents 21 deaths 
caused by the disease compared with 35 deaths without monitoring program, with 
688 years of life gained and an ICER of US$ 670. As demonstrated in other studies, 
the performing monitoring for HCC reduces mortality in the population at risk. The 
clinical pathway implementation of surveillance for HCC in people with liver cirrhosis 
and HBV and HCV infection is very cost effective compared with doing nothing from 
the perspective of third-party payer in Colombia. The results maintain the cost-
effectiveness in the sensitivity analysis without major changes. CONCLUSIONS: The 
implementation of a monitoring method with alpha-fetoprotein and ultrasound every 
two years is cost effective. We recommend the implementation of clinical pathway 
assessed for its cost effectiveness in the light of life years gained as outcome.
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OBJECTIVES: To estimate the incremental cost-effectiveness of bortezomib plus mel-
phalan and prednisone (VMP) compared with melphalan, prednisone and thalidomide 
(MPT) and melphalan plus prednisone (MP) for the treatment of ﬁrst-line multiple 
myeloma in Sweden. METHODS: We constructed a decision-theoretic model, using 
Microsoft® Excel 2007 to compare the VMP, MP and MPT regimens. Treatment 
effects of VMP and MP on progression-free survival and overall survival (OS) were 
obtained from the VISTA trial. Effects of MPT vs. MP were obtained from published 
reports of ﬁve randomized trials. Costs include drug and administration costs, adverse 
events, treatment of relapses, and end-of-life costs. Utility estimates are derived from 
the literature. A mixed treatment comparison meta-analysis indirectly compares VMP 
vs. MPT. The analytic framework is based on ‘partitioned survival analysis’ that 
allows survival data to be decomposed into three states: 1) alive before disease progres-
sion; 2) alive after progression; and 3) dead. The model estimates mean OS, quality-
adjusted life-years (QALYs), costs and cost per QALY over a 30-year time horizon, 
and performs both 1-way and probabilistic sensitivity analyses. RESULTS: VMP’s 
mean OS is 61 months compared to 42.7 and 50.2 months for MP and MPT, respec-
tively. Mean lifetime direct medical costs per patient are approximately SEK 1,193,000, 
604,000 and 920,000 for VMP, MP and MPT, respectively. Mean incremental cost 
per QALY of VMP compared to MP is SEK 676,415; 90 percent C.I. (335,578, 
710,135) and SEK 576,823; 90 percent C.I. (0, 1,444,278) compared to MPT. The 
two most inﬂuential variables in our model are 1) VMP to MP hazard ratio; and 2) 
utility after progression. CONCLUSIONS: VMP and MPT are projected to prolong 
survival relative to MP. Having ICERs less than SEK 700,000, we believe that from 
a Swedish perspective, VMP is cost-effective compared to both MP and MPT.
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VALIDATION OF HEALTH OUTCOMES RESEARCH OF CANCER
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OBJECTIVES: Validation of health outcomes research of cancer becomes critical for 
the quality assessment of outcomes research. In Principles of Good Practice for Deci-
sion Analytic Modeling published by ISPOR Task Force ISPOR Task Force in 2003, 
validation was suggested: internal validation, between-model validation, and external 
& predictive validation. Also, Health Technology Assessment NHS R&D HTA Pro-
gramme published Review of guidelines for good practice in decision-analytic model-
ling in health technology assessment in 2004, suggesting a checklist of Dimension of 
quality: Structure, Data, and Consistency (internal and external). The objective of this 
research is to review and summarize validation activities in cancer outcomes researches 
published between 1998 and 2009. Secondary objective is to identify any changes in 
validation activities post regulatory guidelines. METHODS: The relevant articles are 
